TRI-611 is an investigational, orally active ALK molecular glue degrader developed for ALK-positive non-small cell lung cancer research. This targeted protein degradation strategy may be relevant to tumors with acquired ALK inhibitor resistance and central nervous system involvement. With reported CNS-penetrant properties and activity in preclinical resistant models, TRI-611 represents an emerging approach in precision […]
EPI-326 is an investigational tissue-selective EGFR degrader developed by EpiBiologics for EGFR-driven solid tumors, including EGFR-mutant NSCLC and HNSCC. Learn how this bispecific antibody may reshape targeted oncology. Introduction: Why EGFR Still Matters in Cancer Therapy Epidermal growth factor receptor, commonly known as EGFR, has been one of the most important targets in precision oncology for […]
ECI830 is an investigational, selective CDK2 inhibitor attracting attention in cancer research for its role in cell cycle regulation. By targeting CDK2 activity, ECI830 may help researchers explore tumor proliferation, cyclin E/CDK2 signaling, and therapy resistance mechanisms. It is especially relevant to studies involving HR+/HER2− breast cancer and CCNE1-amplified solid tumors, where abnormal cell cycle […]
TRI-611 is an investigational, orally active ALK molecular glue degrader developed for ALK-positive non-small cell lung cancer research. This targeted protein degradation strategy may be relevant to tumors with acquired ALK inhibitor resistance and central nervous system involvement. With reported CNS-penetrant properties and activity in preclinical resistant models, TRI-611 represents an emerging approach in precision […]
AMX-883 is an orally bioavailable BRD9 molecular glue degrader attracting attention in acute myeloid leukemia research. Unlike traditional inhibitors, AMX-883 is designed to remove BRD9 protein from cells, potentially disrupting chromatin remodeling and leukemia-associated transcriptional programs. By promoting BRD9 degradation through a DCAF16-mediated pathway, AMX-883 offers a useful approach for studying targeted protein degradation beyond […]
BASIC RED 46 is a cationic dye widely used for producing brilliant red to bluish-red shades, especially in acrylic fiber dyeing. Its strong affinity for anionic dye sites makes it suitable for textile coloration, textile printing, paper dyeing, leather finishing, and selected specialty ink or coating applications. In acrylic fibers, BASIC RED 46 offers high […]
BASIC RED 46 is a cationic anthraquinone-based dye renowned for its vibrant red color, high solubility, and excellent substrate affinity. Widely used in textiles, paper, and specialty applications, it offers superior color fastness, thermal stability, and chemical resistance. This article provides an in-depth overview of BASIC RED 46, covering its chemical properties, industrial applications, handling […]
Basic Red 46 is a cationic azo dye known for its vivid red shade, strong coloring strength, and affinity for negatively charged substrates. Its synthesis typically involves diazotization of a triazole-based amine, azo coupling with N-methyl-N-benzylaniline, decarboxylation, and conversion into a cationic salt form. Each stage plays a critical role in shaping the dye’s chromophore, […]
CID-078 is a first-in-class oral macrocyclic inhibitor targeting cyclin A/B-RxL substrate interactions in cancer research. Unlike conventional CDK inhibitors, CID-078 disrupts cyclin-substrate recognition, affecting cell-cycle progression, DNA damage response, and mitotic regulation. It is particularly relevant to tumors with E2F pathway activation, RB1 alteration, and abnormal checkpoint control. Preclinical studies suggest potential activity in difficult-to-treat […]
Retatrutide, also known as LY3437943, is an investigational triple agonist peptide targeting the GIP, GLP-1, and glucagon receptors. As obesity, type 2 diabetes, and metabolic syndrome continue to increase worldwide, multi-receptor peptide strategies are gaining attention in metabolic disease research. Retatrutide is designed to influence appetite regulation, glucose metabolism, energy expenditure, lipid handling, and liver […]